拉考沙胺口服液治疗婴幼儿局灶性癫痫的临床分析

Clinical analysis of lacosamide in the treatment of infantile focal epilepsy

目的 观察拉考沙胺(Lacosamide,LCM)口服液单药或添加治疗4月龄~4岁婴幼儿局灶性癫痫的疗效和安全性。方法 收集2022年3月—2022年9月于苏州大学附属儿童医院采用LCM口服液单药或添加治疗的局灶性癫痫的20例患儿,其中男9例、女11例,平均年龄(22.4±13.0)月龄,分析LCM口服液治疗后1、2、3、4、6个月的疗效及不良反应。LCM口服液起始剂量为2 mg/(kg·d),每周增加2 mg/(kg·d),维持剂量6~12 mg/(kg·d)。结果 对20例患儿随访6个月时,总有效例为17例(85.00%),无发作的累积控制例数15例(75.00%)。结论 LCM口服液在婴幼儿局灶性癫痫中单药或添加治疗中,可以有效减少癫痫发作频率、疗效明显、不良反应少、安全性高,具有较好的临床应用价值。

Objective To observe the efficacy and safety of lacosamide as a monotherapy or as an add-on in the treatment of focal epilepsy in children aged 4 months to 4 years. Methods The study included 20 children with focal epilepsy who received oral LCM monotherapy or add-on therapy in Children’s Hospital of Affiliated to Soochow University from March 2022 to September 2022, including 9 males and 11 females with an average age of(22.4±13.0)months. The curative effects and adverse reactions at 1, 2, 3, 4, and 6 months after LCM treatment were analyzed. The initial dose of LCM was 2 mg/(kg·d) and increased by 2 mg/(kg·d) every week, maintenance dose 6 ~ 12mg/(kg·d).Results During the follow-up period of this study, the total effective cases were 17(85.00%), and the number of controlfree cases was 15(75.00%). Conclusion LCM can effectively reduce the frequency of epileptic seizures in the monotherapy or add-on treatment of infants and young children with focal epilepsy, with few adverse reactions and high retention rate, which has high clinical application value.